先前氟康唑暴露作为HIV阳性患者氟康唑耐药念珠菌病的独立危险因素:一项病例对照研究

J D Cartledge, J Midgley, B G Gazzard
{"title":"先前氟康唑暴露作为HIV阳性患者氟康唑耐药念珠菌病的独立危险因素:一项病例对照研究","authors":"J D Cartledge,&nbsp;J Midgley,&nbsp;B G Gazzard","doi":"10.1136/sti.73.6.471","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To determine if prior fluconazole exposure was an independent risk factor for fluconazole resistant candidosis in HIV positive patients.</p><p><strong>Methods: </strong>Twenty five HIV positive cases with fluconazole resistant oral candidosis were matched by CD4 lymphocyte count and time since first episode of candidosis to 25 HIV positive controls with susceptible candidosis. For each individual a history of prior azole prophylaxis was compiled from computerised pharmacy records and review of case notes.</p><p><strong>Results: </strong>The total days of prior azole therapy prescribed was significantly greater for cases than controls. These differences were attributable to prescriptions for secondary prophylaxis against recurrent candidosis, the cases having received significantly longer continuous azole prophylaxis than controls, with no difference in days of prior azole therapy remaining between the two groups if prophylactic prescriptions were excluded. The total cumulative dose of fluconazole received was significantly higher for cases than controls, though mean daily fluconazole doses did not differ significantly between the two groups.</p><p><strong>Conclusion: </strong>Even after controlling for degree of immunosuppression and duration of recurrent candidosis, the association between prior azole exposure and fluconazole resistant candidosis remains significant and largely reflects differences in the prescription of secondary antifungal prophylaxis.</p>","PeriodicalId":12621,"journal":{"name":"Genitourinary Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1997-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1136/sti.73.6.471","citationCount":"9","resultStr":"{\"title\":\"Prior fluconazole exposure as an independent risk factor for fluconazole resistant candidosis in HIV positive patients: a case-control study.\",\"authors\":\"J D Cartledge,&nbsp;J Midgley,&nbsp;B G Gazzard\",\"doi\":\"10.1136/sti.73.6.471\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To determine if prior fluconazole exposure was an independent risk factor for fluconazole resistant candidosis in HIV positive patients.</p><p><strong>Methods: </strong>Twenty five HIV positive cases with fluconazole resistant oral candidosis were matched by CD4 lymphocyte count and time since first episode of candidosis to 25 HIV positive controls with susceptible candidosis. For each individual a history of prior azole prophylaxis was compiled from computerised pharmacy records and review of case notes.</p><p><strong>Results: </strong>The total days of prior azole therapy prescribed was significantly greater for cases than controls. These differences were attributable to prescriptions for secondary prophylaxis against recurrent candidosis, the cases having received significantly longer continuous azole prophylaxis than controls, with no difference in days of prior azole therapy remaining between the two groups if prophylactic prescriptions were excluded. The total cumulative dose of fluconazole received was significantly higher for cases than controls, though mean daily fluconazole doses did not differ significantly between the two groups.</p><p><strong>Conclusion: </strong>Even after controlling for degree of immunosuppression and duration of recurrent candidosis, the association between prior azole exposure and fluconazole resistant candidosis remains significant and largely reflects differences in the prescription of secondary antifungal prophylaxis.</p>\",\"PeriodicalId\":12621,\"journal\":{\"name\":\"Genitourinary Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1997-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1136/sti.73.6.471\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Genitourinary Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/sti.73.6.471\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genitourinary Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/sti.73.6.471","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

摘要

目的:确定先前氟康唑暴露是否是HIV阳性患者氟康唑耐药念珠菌病的独立危险因素。方法:将25例HIV阳性的氟康唑耐药口腔念珠菌病患者与25例HIV阳性的易感念珠菌病对照进行CD4淋巴细胞计数和首次发病时间的匹配。根据电脑化的药房记录和病例记录,对每个人进行了唑预防史的汇编。结果:病例既往给予唑治疗的总天数明显大于对照组。这些差异可归因于针对复发性念珠菌病的二级预防处方,病例接受持续的唑预防治疗的时间明显长于对照组,如果排除预防性处方,两组之间先前唑治疗的剩余天数没有差异。氟康唑的总累积剂量显著高于对照组,但两组间的平均每日氟康唑剂量无显著差异。结论:即使在控制免疫抑制程度和复发念珠菌病持续时间后,既往唑暴露与氟康唑耐药念珠菌病之间的相关性仍然显著,这在很大程度上反映了二级抗真菌预防处方的差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prior fluconazole exposure as an independent risk factor for fluconazole resistant candidosis in HIV positive patients: a case-control study.

Objectives: To determine if prior fluconazole exposure was an independent risk factor for fluconazole resistant candidosis in HIV positive patients.

Methods: Twenty five HIV positive cases with fluconazole resistant oral candidosis were matched by CD4 lymphocyte count and time since first episode of candidosis to 25 HIV positive controls with susceptible candidosis. For each individual a history of prior azole prophylaxis was compiled from computerised pharmacy records and review of case notes.

Results: The total days of prior azole therapy prescribed was significantly greater for cases than controls. These differences were attributable to prescriptions for secondary prophylaxis against recurrent candidosis, the cases having received significantly longer continuous azole prophylaxis than controls, with no difference in days of prior azole therapy remaining between the two groups if prophylactic prescriptions were excluded. The total cumulative dose of fluconazole received was significantly higher for cases than controls, though mean daily fluconazole doses did not differ significantly between the two groups.

Conclusion: Even after controlling for degree of immunosuppression and duration of recurrent candidosis, the association between prior azole exposure and fluconazole resistant candidosis remains significant and largely reflects differences in the prescription of secondary antifungal prophylaxis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信